Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Sarcoma 1Nasopharyngeal Carcinoma 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 22Radiotherapy, Intensity-Modulated 12Fluorouracil 9Gemcitabine 7Docetaxel 7Cetuximab 5Capecitabine 5pembrolizumab 4nimotuzumab 3nedaplatin 3Radiotherapy 3Radiation 3Carboplatin 3toripalimab 2spartalizumab 2camrelizumab 2anlotinib 2Quality of Life 2Protons 2Paclitaxel 2Nivolumab 2Dexamethasone 2Chemoradiotherapy 2tislelizumab 1raltitrexed 1penpulimab 1icotinib 1fosaprepitant 1famitinib 1endostar protein 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Nasopharyngeal Carcinoma × Medicare Part B × Clear all
NCT03474640 2024-11-22

Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies

TopAlliance Biosciences

Phase 1 Completed
184 enrolled 20 charts
GastrointestinalHead & NeckSarcoma

Nasopharyngeal Carcinoma, Chondrosarcoma, Esophageal Neoplasms, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡